Malantide

About the Target

Malantide is a synthetic dodecapeptide derived from the site phosphorylated by cAMP-dependent protein kinase (PKA) on the β-subunit of phosphorylase kinase, which is a highly specific substrate for PKA with a Km of 15 μM. The mapped target for this entry is Protein kinase A catalytic subunits (PRKACA and PRKACB). In research settings, this mapped target is typically treated as a catalytic or regulatory node whose activity can alter substrate turnover, pathway flux, and stress responses over relatively short experimental time scales. In workflow-oriented studies, investigators often focus on sample quality, assay background, and biochemical workflow performance. For experimental design, that usually means pairing the reagent with direct activity measurements and downstream phenotypic markers.

Research Context

As a substrate-format reagent, it is primarily useful in biochemical workflows that monitor enzymatic activity, substrate conversion, or pathway-dependent modification. In practice, dose-response design, timing, and matched control conditions are important for separating direct target engagement from delayed compensatory responses. Because more than one mapped molecular node is represented in the enrichment, pathway readouts should be interpreted with awareness that the phenotype may integrate multiple signaling inputs.

• link phenotypic changes to catalytic or substrate-based biomarkers rather than relying on a single endpoint
• use timed addition or washout designs when direct and downstream effects need to be separated
• benchmark interpretation with orthogonal pathway controls or reference inhibitors where appropriate

Experimental interpretation should therefore connect early pathway changes with later phenotypic outputs, rather than relying on a single endpoint in isolation.

Format Considerations

Using the regular format helps keep comparative experiments aligned, especially when the same signaling question is being tested across multiple models or readout platforms. In comparative workflows, consistency of preparation, exposure window, and matched controls is often as important as the nominal treatment itself. This is particularly helpful for comparative experiments, benchmark studies, and orthogonal validation in which small differences in formulation or handling can complicate interpretation. For peptide-centered workflows, conclusions are usually strongest when biological readouts are paired with consistent preparation and appropriately matched reference conditions.